z-logo
open-access-imgOpen Access
IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia
Author(s) -
Bartosz Puła,
Krzysztof Jamroziak,
Tomasz Wróbel,
Krzysztof Giannopoulos,
Iwona Hus
Publication year - 2022
Publication title -
deleted journal
Language(s) - English
Resource type - Journals
ISSN - 2720-1015
DOI - 10.5603/hcp.2022.0003
Subject(s) - ighv@ , somatic hypermutation , chronic lymphocytic leukemia , oncology , medicine , malignancy , immunology , antibody , b cell , leukemia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom